Wegovy (Semaglutide for Weight Management): Nutrition Considerations

What the research shows

Common questions

What is Wegovy?

Wegovy is the brand name for semaglutide when prescribed for chronic weight management. Once-weekly subcutaneous injection, titrated from 0.25 mg to 2.4 mg over 16+ weeks. Wegovy and Ozempic are the same molecule with different indications and target doses.

Is Wegovy the same as Ozempic?

Same molecule (semaglutide), different brand and indication. Wegovy is labelled for weight management and uses a higher target dose (2.4 mg weekly). Ozempic is labelled for type 2 diabetes and uses up to 2 mg weekly. In practice many prescribers and insurers have treated the two as interchangeable when one is unavailable.

Why does muscle loss get so much attention with Wegovy?

Wegovy drives the most sustained and substantial caloric deficits in the GLP-1 class, and the typical Wegovy patient is not on concurrent diabetes medications that would prompt additional nutritional monitoring. Without a deliberate protein-and-resistance-training plan, the weight-loss composition skews toward lean mass. Practitioner estimate: up to 40% of weight lost on Wegovy can come from muscle without a plan. This figure is flagged for literature confirmation against STEP trial DEXA substudies.

What side effects are most commonly reported?

In a 2026 Nature Health analysis of 17,937 self-reporting Reddit users on semaglutide formulations (including Wegovy), nausea (39.4%), vomiting (18.0%), fatigue (16.1%), constipation (14.9%), and diarrhea (12.4%) were most commonly reported. Rates were higher than the tirzepatide subset in the same study.

Why do I see low HbA1c on Wegovy?

If you are not diabetic, an HbA1c that drifts into the 4s or a fasting glucose that trends borderline-low typically means you are not eating enough. This is a signal to audit protein and caloric intake, not a positive outcome. Tell your prescriber and dietitian.

Will I lose weight every week?

Not uniformly. STEP 1 showed mean body-weight reduction of 14.9% at 68 weeks with semaglutide 2.4 mg vs 2.4% with placebo, but individual response varies widely. Expect weight to move in trend, not week-to-week. Plateaus are normal and not automatically a sign the medication is failing.

Can I do keto on Wegovy?

Patients without diabetes can generally adopt lower-carbohydrate approaches on Wegovy. The priority is still protein floor and adequate intake. Strict ketogenic diets on top of Wegovy can compound under-eating and fatigue — most practitioners would not start a strict keto diet simultaneously with a Wegovy titration. Patients on SGLT2 inhibitors cannot do keto safely.

What happens when I stop Wegovy?

Appetite typically returns over weeks to months. Some weight regain is common — often substantial — and what was lost as fat tends to return primarily as fat, while muscle losses from treatment do not rebuild spontaneously. The habits and muscle mass built during treatment determine the maintenance outcome more than the medication itself. See /glp-1-nutrition/coming-off-glp-1 for the transition framework.

Is "Wegovy face" real?

The gaunt appearance sometimes associated with rapid weight loss on Wegovy is real but largely preventable. It is driven by pace of loss, inadequate protein, and no resistance training. Losing weight at 1–2% of body weight per month, hitting protein floors, and training 3x weekly reduces gauntness substantially. See /glp-1-nutrition/gaunt-face-and-hanging-skin for the full framing.

What about long-term use?

Wegovy is labelled for chronic use. Some patients will use it indefinitely; others will plan a taper once weight and habits are stable. This is a conversation with your prescriber and care team. Either way, the protein and resistance-training framework holds — long-term weight management does not come from the medication alone.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002. (DOI) (evidence entry →)
2. Sehgal NKR, Tronieri JS, Ungar L, Guntuku SC. Self-reported side effects of semaglutide and tirzepatide in online communities. Nature Health. 2026. Published online April 10, 2026. (DOI)
3. Practitioner case material: Eliana Witchell, MSc, RD, CDE. Clinical notes, 2023–2026. Anonymized.